for the Period Ended 31 July 2023
Directors report | |
Balance sheet | |
Additional notes | |
Balance sheet notes | |
Community Interest Report |
Directors' report period ended
The directors present their report with the financial statements of the company for the period ended 31 July 2023
Principal activities of the company
Directors
The directors shown below have held office during the whole of the period from
1 August 2022 to 31 July 2023
The director shown below has held office during the period of
1 August 2022 to 27 March 2023
The director shown below has held office during the period of
17 June 2023 to 31 July 2023
The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006
This report was approved by the board of directors on
And signed on behalf of the board by:
Name:
Status: Director
As at
Notes | 2023 | 2022 | |
---|---|---|---|
| £ | £ | |
Fixed assets | |||
Tangible assets: | 3 | | |
Total fixed assets: | | | |
Current assets | |||
Debtors: | 4 | | |
Cash at bank and in hand: | | | |
Total current assets: | | | |
Creditors: amounts falling due within one year: | 5 | ( | ( |
Net current assets (liabilities): | | | |
Total assets less current liabilities: | | | |
Total net assets (liabilities): | | | |
Members' funds | |||
Profit and loss account: | | | |
Total members' funds: | | |
The notes form part of these financial statements
The directors have chosen not to file a copy of the company's profit and loss account.
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 July 2023
Basis of measurement and preparation
Turnover policy
Tangible fixed assets depreciation policy
Other accounting policies
for the Period Ended 31 July 2023
2023 | 2022 | |
---|---|---|
Average number of employees during the period | | |
for the Period Ended 31 July 2023
Land & buildings | Plant & machinery | Fixtures & fittings | Office equipment | Motor vehicles | Total | |
---|---|---|---|---|---|---|
Cost | £ | £ | £ | £ | £ | £ |
At 1 August 2022 | | | ||||
Additions | | | ||||
Disposals | ||||||
Revaluations | ||||||
Transfers | ||||||
At 31 July 2023 | | | ||||
Depreciation | ||||||
At 1 August 2022 | | | ||||
Charge for year | | | ||||
On disposals | ||||||
Other adjustments | ||||||
At 31 July 2023 | | | ||||
Net book value | ||||||
At 31 July 2023 | | | ||||
At 31 July 2022 | | |
for the Period Ended 31 July 2023
2023 | 2022 | |
---|---|---|
£ | £ | |
Trade debtors | | |
Total | | |
for the Period Ended 31 July 2023
2023 | 2022 | |
---|---|---|
£ | £ | |
Trade creditors | | |
Taxation and social security | | |
Other creditors | | |
Total | | |
for the Period Ended 31 July 2023
The Company used grant funding to employ a part-time Director of Operations, which provided The Company with the capacity to expand upon previous work and to plan for the future. Grant funding was also used to employ a part-time Healthcare Programmes Officer, to allow for healthcare specific programme delivery – this grant funding continues into the next financial year, with most deliverables due early in 2024.The Company continued to update its website and social media channels with current and relevant information for trans people, non-binary people, service providers and policy makers.The Company made a number of consultation responses on matters relating to trans and non-binary people and provided evidence to the United Nations Independent Expert on Sexual Orientation and Gender Identity when he visited the UK.The Company retained and further developed its reputation for providing well informed, properly researched and accessible information for trans and non-binary people, allies and policy makers, and continued to co-ordinate the UK’s Trans Health Forum.The Company continued to support and campaign for those impacted by issues with NHS phalloplasty & metoidioplasty, running an online peer support group for those affected.The Company published the ‘Transition Access Survey Report’, which detailed the results of a survey of more than 1,000 trans people into their experiences of medical transition and offered a number of policy recommendations.The Company attended a number of conferences and speaking events over the year.The Company ran a programme of free workshops for trans people, focussed on seeking support from their GP and on legal rights and protections.The Company published a set of healthcare-focussed website articles, written by trans and non-binary people who face multiple barriers to accessing healthcare.The Company delivered a webinar for healthcare professionals working within Primary Care and delivered training and consultancy for a number of healthcare providers and healthcare-focussed organisations.
The Company holds regular meetings with volunteers throughout the year to discuss work programmes, particularly around healthcare and possible legislative reform. Work plans are developed in conjunction with these volunteer groups.In the autumn of 2022, the Company published its report into the findings of a survey of over 1,000 trans people in relation to medical transition. The report has been widely cited within professional publications and by professional bodies.In May 2023, the Company commissioned research into the experiences of trans people when seeking healthcare. The report, which will be published in the spring of 2024, will offer guidance on what healthcare professionals can do to ensure that their practice is trans inclusive and supportive.
Directors’ remuneration and related party transactions are detailed in the filed accounts for 2022/23.There were no other transactions or arrangements in connection with the remuneration of directors, or compensation for director’s loss of office, which require to be disclosed
Donations of £121 were made to the Kenyan Refugee Trans Initiative which was in line with donations received by the Company specifically for that purpose.
This report was approved by the board of directors on
5 April 2024
And signed on behalf of the board by:
Name: Helen Belcher
Status: Director